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Protein dynamicThe α4β2 nicotinic acetylcholine receptor (nAChR) has signiﬁcant roles in nervous system function and dis-
ease. It is also a molecular target of general anesthetics. Anesthetics inhibit the α4β2 nAChR at clinically rel-
evant concentrations, but their binding sites in α4β2 remain unclear. The recently determined NMR
structures of the α4β2 nAChR transmembrane (TM) domains provide valuable frameworks for identifying
the binding sites. In this study, we performed solution NMR experiments on the α4β2 TM domains in the ab-
sence and presence of halothane and ketamine. Both anesthetics were found in an intra-subunit cavity near
the extracellular end of the β2 transmembrane helices, homologous to a common anesthetic binding site ob-
served in X-ray structures of anesthetic-bound GLIC (Nury et al., [32]). Halothane, but not ketamine, was also
found in cavities adjacent to the common anesthetic site at the interface of α4 and β2. In addition, both an-
esthetics bound to cavities near the ion selectivity ﬁlter at the intracellular end of the TM domains. Anesthetic
binding induced profound changes in protein conformational exchanges. A number of residues, close to or re-
mote from the binding sites, showed resonance signal splitting from single to double peaks, signifying that
anesthetics decreased conformation exchange rates. It was also evident that anesthetics shifted population
of two conformations. Altogether, the study comprehensively resolved anesthetic binding sites in the α4β2
nAChR. Furthermore, the study provided compelling experimental evidence of anesthetic-induced changes
in protein dynamics, especially near regions of the hydrophobic gate and ion selectivity ﬁlter that directly
regulate channel functions.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Although general anesthesia has been used clinically for over a cen-
tury, the molecular mechanism is still under investigation. Cys-loop re-
ceptors, including nicotinic acetylcholine receptors (nAChRs), are the
important targets of general anesthetics [1,2]. Among many different
subtypes of nAChRs, the α4β2 nAChR is one of the most abundant
nAChRs in the brain [3]. It is involved in memory [4], nociception [5],
and autonomic response [6]. It is highly sensitive to a variety of general
anesthetics. Its current is inhibited by both volatile and intravenous
general anesthetics at clinically relevant concentrations [7–9]. The
α4β2 nAChR shares the same structural architecture as other members
of the Cys-loop superfamily. It forms a pentameric ligand-gated ion
channelwith alternatingα4 andβ2 subunits arranged around the chan-
nel axis in the 3:2 or 2:3 molar ratio [10,11]. Each subunit has an extra-Tower 3, 3501 Fifth Avenue,
5260, USA. Tel.: +1 412 383
l rights reserved.cellular (EC) domain and a transmembrane (TM) domain, which
contains four membrane-spanning helices (TM1-TM4)with TM2 lining
the channel pore. The intracellular (IC) domain contains a large linker
between TM3 and TM4. Dissecting anesthetic action on the α4β2
nAChR will offer valuable insights into the mechanism of anesthetic
modulation on Cys-loop receptors.
To reveal the underlying mechanism of anesthetic inhibition of a
channel protein, an essential task is to identify where anesthetics bind
to the protein.Mutagenesis has beenwidely used to determine residues
showing different functional responses to anesthetics before and after
mutations [12–14]. Such an approach is useful, but it is difﬁcult to dif-
ferentiate direct binding from allosteric action. Photoafﬁnity labeling
has emerged as a powerful tool for identifying speciﬁc protein resi-
dues participating in anesthetic binding [1,15–20]. Analogues of hal-
othane [19], etomidate [18,21,22], and a neurosteroid [16] were
photolabeled onto the Torpedo nAChR or the GABAA receptors. Mul-
tiple binding sites were identiﬁed in the TM domains and other re-
gions of the receptors. Despite considerable progress in developing
new anesthetic analogues for photolabeling [23–25], the choices of
anesthetics for photolabeling are still limited. In addition, large hy-
drophobic patches within the TM domain often hinder amino acid
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tolabeled residues in some channel proteins. X-ray crystallography
can offer high-resolution structural information for anesthetic bind-
ing. A critical issue is whether a good quality crystal is attainable for
the selected protein. Structural determination of eukaryotic Cys-loop
receptors remains a great challenge, but recent successes on structures
of the prokaryotic homologues are certainly encouraging [26–29]. Crys-
tal structures of the ligand-bound ELIC [30,31], especially structural elu-
cidation of anesthetic desﬂurane or propofol binding to the TM domain
of GLIC [32], shed light on molecular recognition of general anesthetics
in Cys-loop receptors. Nuclearmagnetic resonance (NMR) spectroscopy
is yet another powerful technique for structural determinations of ion
channels [33–36] and probing protein-ligand interactions at the atomic
level. Using NMR, we have identiﬁed speciﬁc sites of anesthetic inter-
action within the TM domains of several proteins [37–43]. Further-
more, NMR could resolve site-speciﬁc changes in protein dynamics
introduced by anesthetics [37–39] that are indispensable for under-
standing the functional impact of anesthetic binding.
In this study, we used NMR spectroscopy to examine the plausible
binding sites of the volatile anesthetic halothane and the intravenous
anesthetic ketamine within the TM domains of the α4β2 nAChR. We
previously determined the structures of the entire TM domains of the
α4 (PDB ID: 2LLY) and β2 (PDB ID: 2LM2) nAChRs in LDAO detergent
micelles by solution NMR [35]. We demonstrated that the TM do-
mains of α4 and β2 could assemble into a pentameric pore-forming
structure [35]. We also demonstrated that the assemblies of the TM
domains or even the TM2 helices of α4 and β2 conduct Na+
[35,37]. The high-resolution structure of the α4β2 TM domain pro-
vides an excellent platform for investigating anesthetic binding sites
as well as protein dynamics changes that may be responsible for an-
esthetic inhibition of the α4β2 nAChR. The knowledge of anesthetic
binding sites combined with the dynamic impact on the TM domains
is essential for solving the mystery of anesthetic modulations of the
α4β2 nAChR as well as other Cys-loop receptors.
2. Materials and methods
2.1. Sample preparations
Expression and puriﬁcation of the α4 and β2 TM domains of the
human nAChR as well as the NMR sample preparation were reported
in detail recently [35]. The same protein expression and puriﬁcation
protocols were used for the current study. Each NMR sample contained
0.25–0.3 mM protein, 1–2% (40–80 mM) LDAO detergent, 5 mM sodi-
um acetate pH 4.7, 10 mMNaCl, and 20 mM2-mercaptoethanol to pre-
vent disulﬁde bond formation. 5% D2O was added to the samples for
deuterium lock in NMRmeasurements. To keep adequate NMR spectral
resolution, two types of NMR samples were prepared for investigating
anesthetic binding and the associated dynamic changes. One is
β2(α4), in which β2 is 15N-labeled (NMR observable) and mixed with
the unlabeled α4 (invisible in 15N NMR) in a 3:2 molar ratio. Another
type is α4(β2) that has α4 15N-labeled and mixed with unlabeled β2
in a 3:2 molar ratio. In these individually labeled α4β2 samples, α4
and β2 retained their assembling interfaces and gained better NMR
spectral resolution. The anesthetic ketamine or halothane was titrated
to the samples using amicropipette or a gas-tightmicrosyringe, respec-
tively. The ketamine concentration in the NMR samples was calculated
based on the concentration of a stock solution. The halothane concen-
tration was quantiﬁed based on 19F NMR using the method reported
previously [42].
2.2. NMR data acquisition, processing, and analysis
NMR spectra were acquired on Bruker Avance 600, 700, or 800 MHz
spectrometers at 45 °C. Each spectrometer was equipped with a
triple-resonance inverse-detection cryoprobe, TCI (Bruker Instruments,Billerica, MA). 1H–15N TROSY-HSQC spectra were acquired for each
sample before and after adding anesthetics. Concentrations of halo-
thane and ketamine used for the NMR experiments were up to 8 and
0.3 mM, respectively. Spectral windows of 13 ppm (1024 data points)
in the 1H dimension and 22 or 24 ppm (128 data points) in 15N dimen-
sionwere used. A one second relaxation delaywas used. The speciﬁcα4
and β2 residues affected by anesthetic bindingwere identiﬁed based on
chemical shift changes induced by anesthetics. Since halothane has a
distinct proton resonance that is suitable for saturation transfer used
to determine halothane binding sites, we also performed 2D saturation
transfer experiments using amodiﬁedHSQC pulse sequence [39] on the
β2(α4) andα4(β2) samples containing ~2.0 mMhalothane. The spec-
tra were acquired in an interleaved fashion with on- and off-1H res-
onance frequencies of 6.48 ppm (the halothane proton) and 15 ppm
(blank), respectively. The selective saturation was achieved using an
IBURP2 pulse train (50 ms Gaus1.1000-shaped or rectangular pulses
with an interpulse delay of 4 μs). The total saturation time was 1 s
and the relaxation delay was 1.5 s. The 1D saturation transfer differ-
ence experiments [44] were performed to conﬁrm that the saturation
parameters used in 2D experiments were chosen properly. The 1H
chemical shifts were referenced to the DSS resonance at 0 ppm and
the 15N chemical shifts were indirectly referenced [45].
NMR data were processed using NMRPipe 4.1 and NMRDraw
1.8 [46], and analyzed using Sparky 3.10 [47]. Each processed spec-
trum had 4096×512 data points. 1H and 15N chemical shift assign-
ments for the α4 and β2 TM domains after addition of anesthetics
were referenced to the previous assignments for the same proteins
without drugs [35]. The published pentameric models of α4β2 and
the MATLAB® programming environment were used to analyze in-
teractions between anesthetics and α4β2. Chemical shifts and
peak intensities in the NMR spectra were measured using Sparky
3.10 [47].
2.3. Visualization of anesthetics in the α4β2 nAChR
To assist visualizing anesthetics in the NMR identiﬁed binding sites,
we performed targeted docking of halothane or ketamine to our previ-
ously reported α4β2 model. The targeted docking kept only those sites
consistent with the NMR results. Docking was performed with
Autodock4 [48] using a Lamarckian genetic algorithmwith a grid spac-
ing of 0.402 Å. For each intra-subunit site suggested by the NMR data,
250 independent anesthetic dockings were performed within a cube
covering of ~9000 Å3 located at either the EC or IC end of the TM do-
main. For each inter-subunit site, 500 independent anesthetic dockings
were performed within a ~21×21×42 Å rectangular prism covering
the length of the inter-subunit interface.
3. Results
3.1. Multiple halothane interaction sites in the α4β2 nAChR
Halothane bound to inter- and intra-subunit cavities of the α4β2
TM domains. As exhibited in the 1H-15N HSQC spectra in Fig. 1, the
majority of residues were not affected when 2 mM halothane was
added to either the α4(β2) or the β2(α4) samples. However, some
residues had obvious changes in chemical shift. Full assignments of
the NMR spectra showing halothane effects are provided in Figs. S1
and S2. Direct interactions between halothane and α4β2 were further
demonstrated in 2D saturation transfer experiments [49,50] (Fig. S3).
After the residues showing changes either in chemical shift or satura-
tion transfer were mapped onto the structure of α4β2 (Fig. 2), the
halothane interaction sites became apparent. The β2 subunit has
two intra-subunit halothane binding sites near the EC and IC ends
of the TM domain. The closeness of hydrogen atoms of halothane to
Y212 and V262 (site #1 in Fig. 2) and to T224 and F231 (site #2) fa-
cilitated the observed saturation transfer (Fig. S3). The α4 subunit
Fig. 1. Residues involved in halothane binding using 1H–15N TROSY-HSQC spectra of
the transmembrane domain of the human α4β2 n-acetylcholine receptor in the ab-
sence (black) and presence (green) of 2 mM halothane. (A) α4(β2), where only α4
is 15N-labeled; (B) β2(α4), where only β2 is 15N-labeled. For clarity, the chemical
shift assignment for each peak is omitted here but provided in the Supplementary ma-
terial (Figs. S1 and S2). Peaks displaying signiﬁcant changes in chemical shift are
circled.
Fig. 2.Multiple halothane-binding sites in the α4β2 nAChR. The TM domains of α4 and
β2 are colored in yellow and silver, respectively. Residues of α4 (green) and β2
(orange) are highlighted in the surface presentation if they show direct interactions
with halothane in the 2D saturation transfer experiments or in the stick presentation if
they show changes in chemical shift upon halothane binding. The docked halothane mol-
ecules are numbered and shown in light gray. Note the inter-subunit sites, #4 and #5.
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TM domain. Halothane near the EC end of α4 (#4) more or less resid-
ed between intra- and inter-subunit sites, where residues I268 and
N221, L222 of α4 and K260 and V262 of β2 line the cavity. It appears
that site #4 is open for halothane to sample both intra- and
inter-subunit cavities. Another inter-subunit site for halothane (#5)
is supported by I450 of β2 and L283 of α4, where saturation transfer
was observed (Fig. S3).
Collectively, bothα4 andβ2 have intra-subunit binding sites for hal-
othane. The intra-subunit sites near the EC end and the IC end are ho-
mologous to the anesthetic site identiﬁed in the X-ray structures of
GLIC [32] and a neurosteroid photolabeling site in the β3 subunit of
the GABAA receptor [16], respectively. In addition to the intra-subunit
sites, our NMR data revealed existence of inter-subunit sites for anes-
thetic binding.
3.2. Ketamine interaction sites in the α4β2 nAChR
Compared to volatile anesthetics, such as halothane, the intravenous
anesthetic ketamine inhibits the function of theα4β2 nAChR at a lower
concentration [51]. We added only 80 μM ketamine to the α4(β2) or
β2(α4) samples and observed notable changes in chemical shift forseveral residues in 1H–15N HSQC spectra (Figs. 3, S4 and S5). Severe
overlapping of proton signals of ketamine and protein prevented a reli-
able result from saturation transfer difference experiments. Thus, the
ketamine sites were determined based on chemical shift perturbation.
Two ketamine-binding sites emerged when the ketamine-perturbed
residues were mapped onto the NMR structure of α4β2 (Fig. 4). One
is reminiscent of the intra-subunit halothane site near the EC end of
TM in β2 (Fig. 2). Another is located near the IC end of TM between
β2 and α4, where ketamine contacts I287 of β2 and V234 of α4. Keta-
mine perturbation to these residues propagated to other more remote
residues (V283 and K246) and caused changes in their chemical shifts.
3.3. Anesthetic binding altered dynamics of the α4β2 nAChR
Motional characteristics of proteins are often reﬂected in peak in-
tensities of residues in the NMR spectra [36,52]. Residues at the N-
and C-termini as well as exposed loops experience fast motions (on
the ps–ns timescale) and have higher signal intensities than residues
on helices (Fig. S6). Conversely, residues in the TM helices have weak
intensity or invisible signals due to restricted motion or broadening
due to conformational-exchange on the μs–ms timescale [53].
Upon addition of anesthetics, changes in motion or conformational
exchange for residues in α4β2 are evident in the NMR spectra. The
most remarkable change is splitting of single peaks into double peaks
(for example, V236 and L222 of α4; Fig. 5A). The visibly separated dou-
ble peaks could result from either a decrease in the rate of conforma-
tional exchange or a shift in the conformational distribution [54]. In
the ﬁrst scenario, a single NMR signal was detected when the exchange
rate between the two conformationswas faster than theNMR detection
time scale. The single peaks became double peaks when anesthetics
slowed down the exchange rate. The observed double peaks of V253
and L222 belong to this scenario. For shifting conformation equilibria
by anesthetics, V236 ofα4 gave a good example. In the second scenario,
V236 had two populations (75% vs. 25%) with distinct resonance fre-
quencies in the absence of halothane. The major peak shifted and its
peak intensity dropped in an anesthetic concentration dependent
Fig. 3. Residues involved in ketamine binding using 1H–15N TROSY-HSQC spectra of
the transmembrane domain of the human α4β2 n-acetylcholine receptor in the ab-
sence (black) and presence (green) of 80 μM ketamine. (A) α4(β2), where only α4
is 15N-labeled; (B) β2(α4), where only β2 is 15N-labeled. For clarity, the chemical
shift assignment for each peak is omitted here but provided in the Supplementary
material (Figs. S4 and S5). Peaks displaying signiﬁcant changes in chemical shift
are circled.
Fig. 4. The ketamine-binding sites in the α4β2 nAChR. The TM domains of α4 and β2
are colored in yellow and silver, respectively. The residues of α4 and β2 showing
changes in chemical shift upon halothane binding are highlighted in green and orange
sticks, respectively. The docked ketamine molecules are numbered and shown in light
gray.
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but its intensity increased so that the two conformations became almost
equal populated in the presence of 2 mM halothane. Thus, anesthetics
have either decreased conformational exchange rates or shifted confor-
mation equilibria.
In addition to the change in peak splitting, we observed increased
and decreased signal intensities for some residues. When we high-
light these residues in the structures ofα4 and β2 (Fig. 5), several fea-
tures become clear. Most residues in the vicinity of anesthetic binding
sites experienced dynamic changes. However, dynamic changes in-
duced by anesthetics could extend beyond the binding sites, such as
the case of dynamical changes at the upper helical region of α4
when ketamine bound to the inter-subunit site close to the IC end
of the TM domain. It is also noticeable that loop residues of fast mo-
tion and high NMR signal intensities are not affected by anesthetics,
but residues at junctions of helices and loops (V262 and S271 of β2
and I267, I268, S277 of α4) are susceptible for dynamical modulation
by anesthetics. This observation is consistent with a previous NMR
study on another membrane protein [38].
4. Discussion
4.1. A common general-anesthetic binding site near the EC end of the TM
domain
Both the inhalational anesthetic halothane and the intravenous anes-
thetic ketamine havemultiple interaction sites in the TMdomains of theα4β2 nAChR. This ﬁnding is in accordwith previous computational pre-
dictions [55–59] and experimental observations [15,18,19,60] on the
α4β2 nAChR and its homologous proteins.
Among different sites, the intra-subunit binding site near the EC
end of the TM domain (#1 in Figs. 2 and 4) has been most substanti-
ated by experiments on several homologous proteins. Photo-afﬁnity
labeling of [14C] halothane to the Torpedo nAChR was identiﬁed on
residue δ-Y228 [19], which is homologous to Y212 of β2 lining #1 hal-
othane site (Fig. 2). Fluorescence quenching experiments suggested
halothane binding to an equivalent site in GLIC [60]. Furthermore,
crystal structures of GLIC in complex with the anesthetics desﬂurane
and propofol revealed the intra-subunit anesthetic binding site [32]
that is in remarkable agreement with our NMR identiﬁed site for hal-
othane or ketamine in the β2 subunit (Fig. S7). It is intriguing to see
that in the absence of the EC domain, the TM domain alone presents
the same anesthetic binding site as those intact homologous proteins.
It signiﬁes that our NMR structures for the α4β2 TM domains [35]
well represent the same domains in the intact protein. Halothane
and ketamine have very different molecular volumes and shapes.
Their binding to this upper part of the TM domain of the α4β2
nAChR not only further supports the notion that the site is a common
site for anesthetic binding to pentameric ligand gated ion channels
[32], but also demonstrates the ﬂexibility of the cavity to accommo-
date different anesthetics.
4.2. Additional anesthetic binding sites
Inter-subunit halothane binding sites at the interface of α4 and β2
(#4 and #5 in Fig. 2) are almost at the same height as the intra-subunit
halothane site at the upper part of the TMdomain. Several residues lining
these sites were implicated previously as anesthetic-labeling residues in
homologous proteins. L283 at the inter-subunit halothane-binding
site is homologous to A288 of the α1 glycine receptor, where the
site for alcohol and anesthetic action was rationalized [14,61]. Al-
though the X-ray structures of GLIC bound with desﬂurane or
propofol revealed only the intra-subunit anesthetic binding site,
the study recognized the possibility of anesthetic migration from
intra- into inter-subunit cavities [32]. The NMR identiﬁed halothane
sites (#4 and #5) in Fig. 2 add compelling evidence for anesthetic
Fig. 5. Anesthetics changed dynamics of residues in the α4β2 TM domains. (A) A rep-
resentative expanded region of the 1H–15N TROSY-HSQC spectra for α4(β2) in the ab-
sence (black) and presence (red) of 2 mM halothane. Note the peak splitting for L222
and V236, indicative of slow exchange. (B) Residues experienced dynamics changes
upon halothane binding are highlighted on the α4 (yellow) and β2 (silver) structures.
(C) Residues that experienced dynamics changes upon ketamine binding are highlight-
ed on the α4 (yellow) and β2 (silver) structures. Three scenarios of dynamics changes
are included in both (B) and (C): residues exhibiting peak splitting (cyan), decreases in
peak intensity (blue), and increases in peak intensity (purple). Halothane and keta-
mine are shown in ghost representation to assist viewing each binding site.
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pear in the inter-subunit cavities at the upper part of the TM domain.
The larger size of ketamine may have prevented the molecule from
occupying both intra- and inter-subunit cavities.
Another discrete set of intra- or inter-subunit cavities for anes-
thetic binding was found at the IC end of the TM domain. Halothane
or ketamine binding to this region of the α4β2 nAChR was observed
for the ﬁrst time, but halothane binding to the homologous region in
GLIC (W213 and W217) was detected previously using ﬂuorescence
quenching [60]. The region at the IC end of the TM domain was also
shown for cholesterol binding in the Torpedo nAChR [62]. Neurosteroids
modulate GABAA receptors via binding to the TM domains of the recep-
tors [12,63]. A neurosteroid-binding site at the IC end of the TMdomain
was recently indentiﬁed [16], highlighting the importance of this region
in drug binding and modulating channel functions.
It is worth noting that anesthetic binding is not restricted only to
the TM domain. They may also occupy cavities in the EC domain in
the intact proteins. A recent crystal structure of GLIC in complex
with ketamine shows that ketamine binds to an inter-subunit cavity
in the EC domain and the ketamine binding inhibits GLIC current
[64]. For theα4β2 nAChR, in the absence of the extracellular domain,
the channels formed by the TM domains exhibit spontaneous open-
ing and closing [35]. How much anesthetics increase the probability
of channel closing and which binding site plays the most critical role
in channel inhibition need to be investigated in future studies.4.3. Anesthetic effects on dynamics
Conformational changes in the TM domains of the α4β2 nAChR
constitute different functional states of the ion channel. Even in the
absence of the EC domains and without agonist binding, the TM do-
mains of α4 and β2 could form Na+-conducting channels spontane-
ously in lipid vesicles [35]. Our NMR data show that anesthetic sites
at the EC end of the TM domains are virtually located behind the
channel gate, while the sites at the IC end of the TM domains are ad-
jacent to the ion selectivity ﬁlter. Both locations are crucial to channel
function [32,65,66]. Conformational changes in these regions can af-
fect transitions between different states of ion conductivity through
channels.
Anesthetic modulation on channel motion was evidenced by
changes of NMR signal intensities upon adding anesthetics, as well
as peak splitting of the α4 and β2 residues at the EC and IC ends of
the TM domains. Although changes in peak intensities alone could
not tell whether anesthetics made conformational exchanges slower
or faster, peak splitting unambiguously indicated a decrease in the
conformational exchange rate on a μs–ms timescale [53]. Anesthetic
occupancy of the α4β2 cavities may have reduced the degrees of free-
dom of interacting side chains and the attached backbone atoms, con-
sequently resulting in decrease of exchange rate. For the same reason,
anesthetic binding stabilized the original sub-conformation, shifted
the conformational equilibria, and changed the population distribu-
tion of different conformations. The same trend of decrease in confor-
mational exchange rates caused by anesthetics was also observed on
other proteins [38,39]. The results support the notion that multiple
conformers coexist dynamically in ion channel proteins and general
anesthetics can shift the equilibrium among different conformation
states [67].
It is also imperative to know that dynamics changes occurred not
only to residues adjacent to anesthetics, but also to residues remote
from the anesthetic binding sites. The observation is in accord with
the consensus of allosteric mechanisms of signal transduction [68].
Propagation of local anesthetic perturbation to remote sites, especial-
ly to the junctions of helices and loops, can lead functional conse-
quences. Although ketamine does not bind near I267, I268, and
S277 of α4, the observed motion changes in these residues are likely
403V. Bondarenko et al. / Biochimica et Biophysica Acta 1828 (2013) 398–404to affect communication between the EC and TM domains in the
agonist-elicited channel activations [69,70].
5. Conclusions
The study, for the ﬁrst time, revealed multiple anesthetic binding
sites in the TM domains of the α4β2 nAChR. The identiﬁed intra-
subunit halothane and ketamine sites near the EC end of the TM do-
mains are reminiscent of the previously reported site on homologous
proteins [19,32], supporting the notion that the identiﬁed site is a
common anesthetic site. The inter-subunit sites near the EC end of
the TM domains were observed for halothane but not for ketamine,
suggesting that anesthetics of small sizes can “travel” between
intra- and inter-subunit sites. The sites near the IC end of the TM do-
mains were least documented for anesthetic binding in the literature.
The ﬁnding of halothane and ketamine at these sites certainly adds
more weight to the region.
The study also provided compelling experimental evidence of
anesthetic-induced changes in protein dynamics, especially near re-
gions of the hydrophobic gate and ion selectivity ﬁlter that directly
regulate functions of the channel. Motion is essential for functions, es-
pecially for proteins like the α4β2 nAChR. Our data demonstrated
that anesthetics could shift equilibria of coexisting conformers and
modify the motion on the μs–ms timescale, which is on the same
timescale of channel functions. Thus, these dynamics changes will im-
part a functional consequence. Furthermore, our study demonstrated
dynamics changes beyond the binding sites and allosteric modulation
of anesthetics on protein dynamics, suggesting that anesthetic bind-
ing to a few sites could introduce disturbance to the coupled motion
in the molecular machinery of the α4β2 nAChR and ultimately alter
functions of these proteins.
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